SLC5A2 and heart failure: Future research could investigate the physiological basis for heart failure risks associated with DPP-4 inhibitors and explore how these medications interact with other antidiabetic agents, such as SGLT2 inhibitors, which have shown positive effects on heart failure outcomes.